Navigation Links
ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
Date:4/21/2009

FREDERICK, Md., April 21 /PRNewswire/ -- ImQuest BioSciences and Arisyn Therapeutics jointly announced today the successful acquisition of funding from the National Institutes of Health to support the development of novel small molecule therapeutics for the treatment of hepatitis C virus (HCV) infection. ImQuest scientists will investigate the therapeutic potential and mechanism of action of ATI-0810 (Formerly PG301029) and a series of related chemical compounds. PG301029 is a highly novel transcriptional inhibitor of HCV replication, yielding a significant reduction of viral RNA synthesis in infected cells, and laboratory studies have demonstrated the compound to be less toxic and more active than the FDA approved agent ribavirin. Preliminary in vivo toxicology studies indicate that the compound is well tolerated and has a pharmacokinetic profile appropriate for drug development. The ImQuest research team will be led by Principal Investigator Todd B. Parsley, Ph.D., Director of Hepatitis Virus Research. The funded studies will permit ImQuest to define other potent transcriptional inhibitors of HCV, investigate the mechanism of action of the active molecules and provide additional rationale for the development of a combination anti-HCV therapy using the lead molecules.

"We believe that the addition of a novel agent such as PG301029 to the current standard of care for HCV infected individuals will greatly enhance the percentage of patients that are able to achieve a robust and durable antiviral response to therapy," said Dr. Robert W. Buckheit, Jr., Executive Vice President of ImQuest. "Our data provide adequate rationale for the expedited development of PG301029 for HCV infection, and provide a platform to identify novel cellular and viral targets for future antiviral therapeutic development efforts."

The research continues the collaborative scientific partnership between ImQuest and Arisyn Therapeutics for the dev
'/>"/>

SOURCE ImQuest BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
2. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
3. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
4. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
6. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
7. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
8. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
9. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
10. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
11. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015  New York College of Health Professions announces ... portfolio with U.S. Patent #8,996,098 donated by its Chairman ... a surgical instrument that allows surgeons to view and ... in the traditional format of a slide that is ... during surgery, thus providing the surgeon real time analysis ...
(Date:4/1/2015)... ASPEN, Colo. , April 1, 2015  Astellas ... (CKF), is pleased to sponsor the second annual Bounce ... award, which will recognize two transplant recipients who exhibit ... a career accomplishment, participation in a sport or hobby, ... loved ones. "The Bounce Back Award ...
(Date:4/1/2015)... 2015  The fairness of the proposed acquisition of ... Pharmaceutical Industries ("Teva") is being investigated by WeissLaw LLP, ... investigation focuses on possible breaches of fiduciary duty and ... of ASPX for agreeing to sell the Company to ... definitive agreement for Teva to acquire ASPX in a ...
Breaking Medicine Technology:Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 2Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 3WeissLaw LLP: Auspex Pharmaceuticals Inc. Acquisition By Teva Pharmaceutical Industries May Not Be In The Best Interest of ASPX Shareholders 2
... Recent Highlights: Qutenza ® (capsaicin) ... adoption by large US institutions; 238 hospitals purchased as of 4Q10, ... Q4 2010 revenue totaled $2.3 million including $0.5 million U.S. Qutenza ... in 17 countries at December 31, 2010 NGX-1998 Phase 2 ...
... March 30, 2011 Rochester Medical Corporation (Nasdaq: ... BioSciences N.V. today approved the previously announced sale of ... subsidiary to Rochester Medical Corporation. Rochester Medical ... and under the terms of the Share Purchase Agreement ...
Cached Medicine Technology:NeurogesX Reports Fourth Quarter and Year-End 2010 Results 2NeurogesX Reports Fourth Quarter and Year-End 2010 Results 3NeurogesX Reports Fourth Quarter and Year-End 2010 Results 4NeurogesX Reports Fourth Quarter and Year-End 2010 Results 5NeurogesX Reports Fourth Quarter and Year-End 2010 Results 6NeurogesX Reports Fourth Quarter and Year-End 2010 Results 7NeurogesX Reports Fourth Quarter and Year-End 2010 Results 8NeurogesX Reports Fourth Quarter and Year-End 2010 Results 9Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation 2
(Date:4/1/2015)... April 01, 2015 New Jersey ... by other First Spouses from across the country ... March 21, 2015, World Down Syndrome Day(WDSD), to ... rapidly advancing area of Down syndrome cognition research. ... included Alabama, Alaska, American Samoa, Arizona, California, Colorado, ...
(Date:4/1/2015)... BioPlus Specialty Pharmacy (BioPlus), one ... a new app to keep health care providers informed ... C virus (HCV) infection. This ‘HCV Treatment Path’ app ... American Association for the Study of Liver Diseases (AASLD) ... oral medications to treat HCV have been approved by ...
(Date:4/1/2015)... 2015 Dr Roz Kamani, a Vancouver ... now offering her patients an opportunity to learn more ... in “Beauty Days”, which is an exclusive VIP event ... Kitsilano Skin Care Clinic. It is attended by Dr ... the latest products and services that are on offer. ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 South Florida’s ... Provisional Certificate of Authority (PCOA) approval from the State ... in the ongoing development of a retirement community that ... health, wellness and spiritual development. , America’s aging population ... meet the housing needs of seniors, according to a ...
(Date:4/1/2015)... PA (PRWEB) April 01, 2015 Health ... company and a subsidiary of West Corporation, today launched ... at http://blog.healthadvocate.com and through the Health Advocate ... healthcare consumers get, and stay, healthy. , “We’re pleased ... available to the public,” said Martin Rosen, Executive Vice ...
Breaking Medicine News(10 mins):Health News:Governor First Spouses Join with New Jersey First Lady Mary Pat Christie to Support Advances in Biomedical Research to Treat Down Syndrome Cognitive Impairment 2Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:Casa Sant’Angelo Receives Approval for New Retirement Living 2Health News:Health Advocate Launches New Health and Wellness Blog 2
... HMSY ) today announced that it will present at the William ... held June 9 - 11 at The Four Seasons Hotel in ... 10th at 4:00 p.m. CT. , , HMS Holdings ... integrity services for government healthcare programs. The Company,s clients include health ...
... 8, 2009 Ontario children are more likely to get ... of the Institute for Clinical Evaluative Sciences (ICES) has found ... of diabetes in Ontario children from 1994 to 2004. ... major health problems. Most children with diabetes have Type 1, ...
... study finds , MONDAY, June 8 (HealthDay News) -- ... the world,s most influential medical journals, a new study ... learning all they can about gender differences in response ... 661 prospective studies about types of cancer that afflict ...
... and Accountability in Kidney Care, to reduce mortality by 20 ... , , WASHINGTON, June 8 Kidney ... campaign pledging to reduce mortality among first-year dialysis patients -- ... the end of 2012. , , The ...
... , , Aspirin a Day, Other Services Cited ... WASHINGTON, June 8 As Congress tackles health reform, a new ... saved every year by investing in five basic preventive services. That ... who could benefit were advised by their doctors to take a ...
... and Rochester , ... According to New Reports from HealthLeaders-InterStudy , , ... managed care market intelligence, reports that medical home pilot initiatives ... determine whether such programs can save money by directing care ...
Cached Medicine News:Health News:Still Too Few Women in Cancer Trials 2Health News:Still Too Few Women in Cancer Trials 3Health News:Kidney Care Partners Launches Health Care Campaign to Improve Survival Rates of First-Year Dialysis Patients 2Health News:Kidney Care Partners Launches Health Care Campaign to Improve Survival Rates of First-Year Dialysis Patients 3Health News:U.S. Could Save 100,000 Lives a Year with Five Basic Preventive Services 2Health News:Medical Home Pilot Initiatives Continue to Expand Nationwide 2Health News:Medical Home Pilot Initiatives Continue to Expand Nationwide 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: